China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture (JV) with Indonesia’s leading pharmaceutical company, PT Kalbe Farma, TBK. The JV, with a registered capital valued at approximately RMB 582 million, will focus on the manufacturing of active pharmaceutical ingredients (APIs) in Southeast Asia.
Under the terms of the agreement, PT Kalbe Farma will be granted the distribution rights for the JV’s products across Southeast Asia. This strategic partnership aims to leverage Livzon’s expertise in API manufacturing and Kalbe Farma’s established distribution network to enhance the presence of both companies in the region’s pharmaceutical market.- Flcube.com
